X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in adult and pediatric patients aged 12 and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in adult and pediatric patients aged 12 and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Empaveli (pegcetacoplan) is the first treatment for PNH that binds to the complement protein C3, which is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: OrphanDC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, in Latin America.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: Besremi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: PharmaEssentia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 02, 2023
Details:
Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioCryst Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Under the terms of the agreement, Pint Pharma will be responsible for obtaining and maintaining all marketing authorizations and for commercializing ORLADEYO in the pan-LATAM region.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
